Estrella Immunopharma (ESLA) Total Non-Current Liabilities (2023 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Total Non-Current Liabilities of $8.5 million for Q1 2026, down 35.83% quarter-over-quarter from $13.2 million in Q4 2025.
Estrella Immunopharma (ESLA) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Total Non-Current Liabilities for 4 consecutive years, with $8.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (changed N/A YoY), while the FY2025 annual figure was $13.2 million, up 392.27% from the prior year.
- Total Non-Current Liabilities retreated to $8.5 million in Q1 2026 per ESLA's latest filing, from $13.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $17.3 million in Q3 2023 and bottomed at $12725.0 in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $6.1 million across 4 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 82.7% — and 2025, when it soared 4818.21%.
- Estrella Immunopharma's Total Non-Current Liabilities stood at $398733.0 in 2023, then soared by 571.81% to $2.7 million in 2024, then soared by 392.27% to $13.2 million in 2025, then slumped by 35.83% to $8.5 million in 2026.
- Business Quant data shows ESLA's Total Non-Current Liabilities at $8.5 million in Q1 2026, $13.2 million in Q4 2025, and $13.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 8.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.57 Mn |
| Mar 31, 2026 | 8.46 Mn |
| Dec 31, 2025 | 13.19 Mn |
| Sep 30, 2025 | 12.97 Mn |
| Jun 30, 2025 | 8.89 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 180,701.00 |
| Mar 31, 2024 | 138,491.00 |
| Dec 31, 2023 | 398,733.00 |
| Sep 30, 2023 | 17.28 Mn |
| Jun 30, 2023 | 12,725.00 |